Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dhodapkar

Showing results (121-130 of 158) with videos related to

Pageof 16
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoRituparna Das, Rakesh Verma, Mario Sznol, et al.
British Journal of Haematology|November 11, 1999
High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemiaR Desikan, M Dhodapkar, D Siegel, et al.
Bone Marrow Transplantation|March 14, 2000
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan aloneK R Desikan, G Tricot, M Dhodapkar, et al.
Cancer Research|August 28, 2001
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccineJ Banchereau, A K Palucka, M Dhodapkar, et al.
Nature Methods|November 3, 2023
Causal identification of single-cell experimental perturbation effects with CINEMA-OTMingze Dong, Bao Wang, Jessica Wei, et al.
The Journal of Clinical Investigation|January 9, 2018
Early B cell changes predict autoimmunity following combination immune checkpoint blockadeRituparna Das, Noffar Bar, Michelle Ferreira, et al.
Blood Cancer Journal|March 26, 2016
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)X Papanikolaou, A Rosenthal, M Dhodapkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2025
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell LymphomaFanyuan Zeng, Hanwen Zhang, Shuhua Wang, et al.
Blood Advances|February 6, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myelomaSayalee V Potdar, Shivani Kapadia, Maryam I Azeem, et al.
Nature Cancer|August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trialShambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Pageof 16

Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoRituparna Das, Rakesh Verma, Mario Sznol, et al.
British Journal of Haematology|November 11, 1999
High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemiaR Desikan, M Dhodapkar, D Siegel, et al.
Bone Marrow Transplantation|March 14, 2000
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan aloneK R Desikan, G Tricot, M Dhodapkar, et al.
Cancer Research|August 28, 2001
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccineJ Banchereau, A K Palucka, M Dhodapkar, et al.
Nature Methods|November 3, 2023
Causal identification of single-cell experimental perturbation effects with CINEMA-OTMingze Dong, Bao Wang, Jessica Wei, et al.
The Journal of Clinical Investigation|January 9, 2018
Early B cell changes predict autoimmunity following combination immune checkpoint blockadeRituparna Das, Noffar Bar, Michelle Ferreira, et al.
Blood Cancer Journal|March 26, 2016
Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)X Papanikolaou, A Rosenthal, M Dhodapkar, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2025
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell LymphomaFanyuan Zeng, Hanwen Zhang, Shuhua Wang, et al.
Blood Advances|February 6, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myelomaSayalee V Potdar, Shivani Kapadia, Maryam I Azeem, et al.
Nature Cancer|August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trialShambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Pageof 16